At the 2019 Gastrointestinal Cancers Symposium, important new clinical data were presented on molecular testing, novel immunotherapy strategies, short-course radiation, and low-dose regorafenib in colorectal cancer.
Many of our patients with metastatic CRC can now plan on receiving 3 or more lines of therapy. Read how I approach sequencing and dosing with regorafenib and TAS-102 in my practice.
In this commentary, I provide my thoughts on the management of select patient cases and examine treatment choices made for these cases by 5 experts in CCO’s Interactive Decision Support Tool.
You are accessing CCO's educational content today as a Guest user.
If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.